BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2020-03-11. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenue
9
9
9
10
13
11
Revenue Growth (YoY)
0%
0%
-10%
-23%
18%
--
Cost of Revenue
8
8
8
9
11
9
Gross Profit
1
1
1
1
2
1
Selling, General & Admin
4
3
4
1
1
1
Research & Development
0
0
0
--
--
--
Operating Expenses
3
2
3
1
1
0
Other Non Operating Income (Expenses)
--
--
--
--
--
--
Pretax Income
-2
-1
-2
0
1
1
Income Tax Expense
0
0
0
0
0
0
Net Income
-2
-1
-2
0
0
1
Net Income Growth
--
-50%
--
--
-100%
--
Shares Outstanding (Diluted)
1.79
1.78
1.58
1.44
1.42
0.85
Shares Change (YoY)
0%
12%
10%
1%
66%
19%
EPS (Diluted)
-1.27
-0.89
-1.65
-0.24
0.52
1.27
EPS Growth
146%
-46%
590%
-146%
-59%
-474%
Free Cash Flow
-2
-2
-1
0
0
0
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
11.11%
11.11%
11.11%
10%
15.38%
9.09%
Operating Margin
-22.22%
-11.11%
-22.22%
0%
7.69%
9.09%
Profit Margin
-22.22%
-11.11%
-22.22%
0%
0%
9.09%
Free Cash Flow Margin
-22.22%
-22.22%
-11.11%
0%
0%
0%
EBITDA
-2
-1
-2
0
1
1
EBITDA Margin
-22.22%
-11.11%
-22.22%
0%
7.69%
9.09%
D&A For EBITDA
0
0
0
0
0
0
EBIT
-2
-1
-2
0
1
1
EBIT Margin
-22.22%
-11.11%
-22.22%
0%
7.69%
9.09%
Effective Tax Rate
0%
0%
0%
0%
0%
0%
Follow-Up Questions
What are BioNexus Gene Lab Corp's key financial statements?
According to the latest financial statement (Form-10K), BioNexus Gene Lab Corp has a total asset of $10, Net loss of $-1
What are the key financial ratios for BGLC?
BioNexus Gene Lab Corp's Current ratio is 5, has a Net margin is -11.11, sales per share of $5.05.
How is BioNexus Gene Lab Corp's revenue broken down by segment or geography?
BioNexus Gene Lab Corp largest revenue segment is Trading of Industrial Chemicals, at a revenue of 9,494,577 in the most earnings release.For geography, Malaysia is the primary market for BioNexus Gene Lab Corp, at a revenue of 7,455,906.
Is BioNexus Gene Lab Corp profitable?
no, according to the latest financial statements, BioNexus Gene Lab Corp has a net loss of $-1
Does BioNexus Gene Lab Corp have any liabilities?
yes, BioNexus Gene Lab Corp has liability of 2
How many outstanding shares for BioNexus Gene Lab Corp?
BioNexus Gene Lab Corp has a total outstanding shares of 1.79